<DOC>
	<DOC>NCT02678156</DOC>
	<brief_summary>The aim of this Post Market Clinical Follow-up Study is to collect clinical data on the performance of Lyoplant® Onlay. To assess the performance of the product, various safety and efficacy parameters have been selected.</brief_summary>
	<brief_title>Assessment of the Performance of LYoplant® ONlay for Duraplasty</brief_title>
	<detailed_description />
	<criteria>Patients undergoing an elective cranial or spinal surgery, probably with the need of a duraplasty using Lyoplant® Onlay Written informed consent Life expectancy &gt; 6 months Age &gt; 18 years Active local or systemic infections Open cranial trauma Open spina bifida Known hypersensitivity to proteins of bovine origin Representation by a legal guardian or under involuntary commitment Pregnancy Participation in another clinical study Known primary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dura mater substitute</keyword>
	<keyword>Graft</keyword>
	<keyword>Lyoplant</keyword>
	<keyword>Lyostypt</keyword>
	<keyword>Lyoplant onlay</keyword>
	<keyword>Xenograft</keyword>
</DOC>